NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results

#1508

Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.

Aim(s): Evaluate the activity and safety of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with advanced, progressive sstr positive midgut NETs.

Materials and methods: 230 patients grade 1-2 metastatic midgut NETs were randomized to Lutathera 7.4 GBq every 8 weeks (x4 administrations) vs Octreotide LAR 60 mg every 4 weeks. Primary endpoint was PFS (RECIST 1.1) with tumor assessment every 12 weeks. Secondary objectives included ORR, OS, toxicity and QoL.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Strosberg J

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: Lutathera, PRRT, NET,